File this under ‘best of luck.’ One week after the FDA rescinded a special protocol agreement that Amarin was counting on to significantly widen usage for its Vascepa prescription fish oil pill, the drugmaker has filed an appeal. Whether the agency will change its collective mind is unclear, but a reversal is likely to be a long shot, at best. The effort is the latest twist in what has been one of the more closely watched biopharma stock stories on Wall Street this year.
Help employers find you! Check out all the jobs and post your resume.
